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CATALYSTS FOR BIOMEDICAL
RESEARCH
A common piece of advice when mentor-
ing biomedical researchers preparing their
first grant proposals is to focus on a specific
disease or narrow range of conditions. The
assumption is that proposing to investigate
the pathological aspects of a problem – to
study deviation from homeostasis – makes
for a stronger project than approaching
research through the lens of physiology,
the study of the homeostatic state. Using
the discovery of the adipokines leptin
and adiponectin as an example, I ques-
tion this assumption and discuss how both
approaches can generate excellent research.
LEPTIN AND ADIPONECTIN:
BEGINNING WITH PATHOLOGY
VERSUS PHYSIOLOGY
Adipokines are messenger proteins pro-
duced by adipocytes; they regulate a vari-
ety of functions from appetite to metab-
olism, inflammation, reproduction, and
more (1). Leptin and adiponectin are the
two best-known adipokines: leptin mostly
regulates appetite, though it also pro-
foundly affects metabolism, reproduction,
and immunity, whereas adiponectin is for
the most part involved in modulation of
metabolic responses and inflammation (2).
Both discovered in the mid-1990s, lep-
tin and adiponectin were initially identi-
fied through conceptually distinct research
approaches (3–7). In fact, while the dis-
covery of leptin can be thought of as part
of the process of investigation into the
pathological causes of obesity, adiponectin
was instead isolated via experiments whose
purpose can best be described as aimed
at improving our understanding of basic
adipocyte biology.
Comparing sentences from the origi-
nal articles reporting the discovery of these
two adipokines can help better clarify this
point. In the introduction to their 1994
Nature report describing the identifica-
tion of leptin, Zhang and colleagues wrote:
“Obesity is the commonest nutritional dis-
order in Western societies” and “The mol-
ecular pathogenesis of obesity is unknown”
(7). The stated impetus for research here
is clearly a pathological condition, obesity,
and the aim is “the cloning and sequenc-
ing of the mouse obesity gene and its human
homologue.” (7). These concepts can be
contrasted with those presented in the
four articles describing the discovery of
adiponectin that appeared in 1995–1996
(3–6). Here the authors used very dif-
ferent words to introduce their findings:
“Adipocytes secrete several proteins poten-
tially important in homeostatic control of
glucose and lipid metabolism” (6); “Increas-
ing evidence [ . . .] suggests that adipose tis-
sue produces and secretes several proteins
[ . . .] thought to regulate adipose tissue func-
tion and to affect the metabolism of the
whole body” (4); “Molecules secreted from
adipose tissue are capable of modulating
diverse functions in fat and other tissues,
thus representing a new facet of adipose tis-
sue physiology” (3); “We assumed that there
might be plasma proteins that bind to colla-
gen fibers [ . . .] and searched for such novel
plasma proteins” (5). As these quotes illus-
trate, each of the research teams that inde-
pendently discovered adiponectin framed
their investigation in terms of search-
ing for potential factors that might influ-
ence homeostasis and regulate physiologi-
cal functions.
Statements from the discussion sections
of the two groups of articles are also
illuminating. Compare this sentence from
the leptin paper, “Identification of ob now
offers an entry point into the pathways
that regulate adiposity and body weight and
should provide a fuller understanding of the
pathogenesis of obesity” (7), to words from
the adiponectin reports, “We do not yet
know the function of Acrp30” (6), “The role
of the apM1 protein is not clear at present ”
(4), “The identification of adipo-Q [ . . .]
poses many questions regarding its molecular
and biochemical properties that are yet to be
examined” (3). (The original names for the
leptin gene – ob – and for adiponectin –
Acrp30, adipo-Q, and apM1 – are used in
these sentences.) While the leptin paper
presents the discovery as leading to a bet-
ter understanding of a specific pathology,
each of the adiponectin reports leaves the
doors open as to the potential meaning
of their findings. Thus, even though stud-
ies leading to the discovery of leptin and
adiponectin can both be classified as basic
research, the difference in approach and
conclusions could not be clearer: under-
standing a pathological state in the case of
leptin versus clarifying the normal biology
of cells and tissues for adiponectin. More-
over, the discovery of leptin can be framed
as identification of the gene long known to
be involved in obesity, therefore falling into
the category of specific hypothesis-driven
research. In contrast, each of the projects
that led to the discovery of adiponectin
could easily be criticized for being a“fishing
expedition.”
DEVELOPMENTS OF RESEARCH ON
LEPTIN AND ADIPONECTIN
Just a few months after cloning of the leptin
gene, the effect of leptin injections in reduc-
ing the body weight of mice were reported
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by three different groups in the same issue
of Science (8–10). A news report comment-
ing on these findings discussed the acquisi-
tion of the license to develop leptin by the
biotech company Amgen and the potential
for turning the discovery into obesity drugs
(11). Given the public health and financial
issues at stake, Phase 1 and 2 studies were
conducted with unusual swiftness, showing
that leptin was safe, but also that its effec-
tiveness in curbing appetite and reducing
obesity was variable and less than stellar
(12). Meanwhile, data began accumulating
on the pathophysiological changes in leptin
production and signaling that take place in
obese subjects (13), eventually leading to
realization of the unfeasibility and lack of
strong biological basis for using leptin as
a therapeutic approach to obesity. In the
early-to-mid 2010s, a modified version of
the protein, metreleptin, was approved in
several countries as a therapy for general-
ized lipodystrophy, a rare condition char-
acterized by extremely low levels of leptin.
Injections of leptin are also the only avail-
able life-saving treatment for the handful
of individuals with congenital leptin defi-
ciency. Despite the relative disappointment
of leptin as a blockbuster drug for obesity,
the study of leptin’s biology has literally
revolutionized the way we understand the
physiology of appetite and metabolic regu-
lation. The importance of leptin’s discovery
for scientists working on these basic prob-
lems, and for people with those rare con-
ditions for which leptin is effective, cannot
be overstated.
Much like its discovery, the history of
adiponectin’s research can also be con-
strued as somewhat opposed to that of
leptin. It took three full years before the
initial hunch that obesity is associated
with reduced adiponectin levels (3) was to
be reexamined (14). There were only 34
primary research articles on adiponectin
in the first 5 years after its discovery, as
opposed to the more than 2000 on leptin,
and it was not until 2001 that adiponectin
made it to the pages of high-impact jour-
nals (15, 16). Research then proceeded
swiftly, with publications increasing expo-
nentially. A whole lot of excellent biol-
ogy went into the characterization of
adiponectin as the “good adipokine” that
promotes healthy metabolism and con-
trols inflammation (17). Adiponectin ago-
nists that may in the not-too-distant future
potentially be used for promoting meta-
bolic health and perhaps treat diabetes and
other obesity co-morbidities should clini-
cal studies demonstrate efficacy were iden-
tified in 2013 (18). As much as leptin revo-
lutionized the biology of appetite, the dis-
covery and characterization of adiponectin
has had a radical, far-reaching effect on our
understanding of the regulation of whole-
body metabolic pathways. The concept of
healthy cells producing proteins that act
as messengers of health, as contrasted to
diseased cells generating messages of dis-
tress, has had meaningful impact not only
for the field of obesity and metabolism
but as an overall framework to conceptu-
alize the relationship between health and
disease (19).
THE STORIES WE TELL
The history of the discovery of leptin and
adiponectin can be used as a case in point
to illustrate the importance of the log-
ical frameworks used to justify biomed-
ical research. Although it is well possible
that the discoverers of leptin were actu-
ally more interested in the basic biology
of appetite than in contributing to under-
stand the pathophysiology of obesity, they
chose to construe their findings in light
of disease rather than health, of pathol-
ogy instead of physiology. In contrast, the
discovery of adiponectin was portrayed as
an effort to understand the basic physiol-
ogy of adipose tissue and collagen-binding
proteins, with only passing reference to
the potential medical implications of the
findings.
Historians and philosophers of science
tell researchers that what goes into scientific
reports is not to be trusted, obviously refer-
ring not to the data presented but rather
to the story being told, to the narrative
used to explain and justify the purpose
and meaning of a particular study. Nobel
Prize winner Peter Medawar wrote: “It is
no use looking to scientific papers, for they
not merely conceal but actively misrepre-
sent the reasoning that goes into the work
they describe”(20), calling the outcome“the
studied hypocrisy expected of a contribution
to a learned journal” (21). The same con-
cept can easily be applied to the writing of
research proposals, which need to construe
a credible, logical train of thought for the
critical eye of the reviewer. But here indeed
lies the crux of the matter, since the way we
decide to narrate our “studied hypocrisy”
is telling of the way scientists and, as a
consequence, the general public perceives
what is to be valued and important and
what is not. By choosing to tell our stories
in terms of disease rather than health, of
pathology versus physiology, are we favor-
ing a view that sees health as a passive state?
Our bodies spend an incredible amount of
energy (meant here in its physical form of
calories and ATP, not as a metaphor) to
actively promote health. To name just a few,
adipocytes produce and release tremen-
dous amounts of adiponectin – sufficient
to maintain plasma levels in the tens of
micrograms per milliliter range – that
causally contribute to metabolic homeosta-
sis; endothelial cells fine-tune production
of nitric oxide to maintain appropriate vas-
cular responsiveness; a complex network
of signals allows for the presence of a
functional pool of T regulatory cells that
tame immune responses; sustained levels
of autophagy recycle damaged and dys-
functional cellular components. Yet, these
health-promoting mediators and responses
are more often than not studied in the con-
text of disease, not health. It is perhaps
only a subtle change of perspective, but
telling the story as originating from dis-
ease rather than health perpetuates a view
that sees health as merely the absence of
disease.
We should therefore ask ourselves
whether we are using the right approach
by emphasizing pathology over physiology
as the rationale for important biomedical
research, a choice that may lead to dis-
count and ignore projects with potential
for significant impact while contributing to
perpetuate an outdated concept of passive
health and static physiology. As exemplified
by the history of adiponectin and leptin,
conceptualizing research as answering to
either health or disease has equal chances
to produce outstanding science.
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